Nuveen Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-137,973
| Closed | -$392K | – | 3333 |
|
|
2024
Q1 | $392K | Sell |
137,973
-883,684
| -86% | -$2.51M | ﹤0.01% | 3039 |
|
|
2023
Q4 | $15M | Buy |
1,021,657
+21,306
| +2% | +$314K | ﹤0.01% | 1338 |
|
|
2023
Q3 | $18.3M | Buy |
1,000,351
+447,277
| +81% | +$8.19M | 0.01% | 1093 |
|
|
2023
Q2 | $11.9M | Sell |
553,074
-58,858
| -10% | -$1.27M | ﹤0.01% | 1389 |
|
|
2023
Q1 | $18M | Buy |
611,932
+15,878
| +3% | +$466K | 0.01% | 1113 |
|
|
2022
Q4 | $22M | Buy |
596,054
+239,367
| +67% | +$8.84M | 0.01% | 974 |
|
|
2022
Q3 | $6.39M | Buy |
356,687
+317,200
| +803% | +$5.68M | ﹤0.01% | 1752 |
|
|
2022
Q2 | $761K | Buy |
39,487
+26,257
| +198% | +$506K | ﹤0.01% | 2901 |
|
|
2022
Q1 | $170K | Buy |
+13,230
| New | +$170K | ﹤0.01% | 3215 |
|